Saltar al contenido
Merck

1708707

USP

Valproic acid

United States Pharmacopeia (USP) Reference Standard

Sinónimos:

2-Propylpentanoic acid, Valproic acid

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula lineal:
(CH3CH2CH2)2CHCO2H
Número de CAS:
Peso molecular:
144.21
EC Number:
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

valproic acid

manufacturer/tradename

USP

refractive index

n20/D 1.425 (lit.)

bp

220 °C (lit.)

density

0.9 g/mL at 25 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CCCC(C(O)=O)CCC

InChI

1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)

InChI key

NIJJYAXOARWZEE-UHFFFAOYSA-N

Gene Information

human ... ALDH5A1(7915)

¿Está buscando productos similares? Visita Guía de comparación de productos

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Valproic acid USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Divalproex Sodium
  • Divalproex Sodium Delayed-Release Capsules
  • Divalproex Sodium Delayed-Release Tablets
  • Divalproex Sodium Extended-Release Tablets
  • Valproate Sodium Injection
  • Valproic Acid
  • Valproic Acid Capsules

Biochem/physiol Actions

Anticonvulsant that also has efficacy as a mood stabilizer in bipolar disorder

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Eye Dam. 1 - Repr. 1A - Skin Irrit. 2

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

231.8 °F - closed cup

flash_point_c

111 °C - closed cup


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Mattias Linde et al.
The Cochrane database of systematic reviews, 6(6), CD010611-CD010611 (2013-06-26)
Some antiepileptic drugs but not others are useful in clinical practice for the prophylaxis of migraine. This might be explained by the variety of actions of these drugs in the central nervous system. The present review is part of an
Ivana Rosenzweig et al.
Neuroscience and biobehavioral reviews, 36(8), 1848-1856 (2012-06-02)
Neuropsychiatric medications that directly alter the epigenome, such as valproic acid, can under certain conditions reactivate critical developmental periods and thus impact adult neuroconnectivity. In animal models valproic acid was shown to inhibit the process of postnatal myelination and to
Florence I Roullet et al.
Neurotoxicology and teratology, 36, 47-56 (2013-02-12)
Valproic acid (VPA) is both an anti-convulsant and a mood stabilizer. Clinical studies over the past 40 years have shown that exposure to VPA in utero is associated with birth defects, cognitive deficits, and increased risk of autism. Two recent
Radu M Nanau et al.
Clinical biochemistry, 46(15), 1323-1338 (2013-06-25)
Valproic acid is a widely-used first-generation antiepileptic drug, prescribed predominantly in epilepsy and psychiatric disorders. VPA has good efficacy and pharmacoeconomic profiles, as well as a relatively favorable safety profile. However, adverse drug reactions have been reported in relation with
Periyasamy Palsamy et al.
Experimental eye research, 121, 26-34 (2014-02-15)
Recent epidemiological studies confirm the prevalence of cataract in epileptic patients. Similarly, the drugs used to treat epilepsy also show the connection with increased cataract formation. In this present study, we investigated the suppression of Nrf2/Keap1 dependent antioxidant protection through

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico